EC approves Takeda ADC plus chemo for stage IIb Hodgkin’s lymphoma
The European Commission (EC) has granted approval for Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin).
The European Commission (EC) has granted approval for Takeda's antibody-drug conjugate (ADC) Adcetris (brentuximab vedotin).
What's Your Reaction?
